Combined Effects of Plyometric and Endurance Training Among Female Hockey Players

July 15, 2024 updated by: Riphah International University

Combined Effects of Plyometric and Endurance Training on Speed, Agility and Strength Among Female Hockey Players

Athletes need plyometric training as well as endurance training to enhance their speed, strength and agility in the field. Plyometric exercise involves stretching the muscle immediately before making a rapid concentric contraction. The combined action is commonly called a stretch-shortening cycle (SSC). Similar gains of maximal strength have been reported with traditional strength and plyometric training, but the latter approach appears to induce greater gains in muscle power. The combination of balance and muscle strength/power exercises seems to be an appropriate possibility, since both modalities induced adaptation on the neuromuscular level. A blocked combination of balance and muscle strength exercises effectively improve physical performance, and improvements in performance are more pronounced if balance exercises are followed by strength exercises than vice versa.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Strength and endurance training are often done concurrently by fitness enthusiasts and athletes. Concurrent strength and endurance training however, result in "antagonism" of the training responses. Combined strength and endurance training in previously untrained subjects has developed strength impairment in comparison to strength training alone, whereas endurance development, expressed as increases in maximal aerobic power has not been impaired. A combination of some forms of strength and endurance training maybe "addictive" rather than antagonistic. Some endurance training programs have increases strength and muscle fiber size. A randomized controlled trial will be conducted. Non-probability convenient sampling technique will be used. Study will be carried in hockey clubs at Lahore. Only female players of age 18-24 with one year experience in hockey, only players who will participate in all training sessions will be included in the statistical analysis. Participants with the history of systemic disease, with history of lower extremity and lumber spine pathology, with prior surgery history and participants having injuries resulting in loss of one or more hockey matches/ training sessions in the preceding three months prior to the initiation of the study will be excluded. Three groups will be included in the study each containing 10 participants. Group A will be given plyometric training for 12 weeks, Group B will be given endurance training for 12 weeks and Group C will be given both trainings for 12 weeks. Pre-training values will be taken prior training. Mid-training values will be taken after 6 weeks of training and post-training values will be taken after training.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • Recruiting
        • Pakistan Sports Academy
        • Sub-Investigator:
          • Syed Asadullah Arslan, PhD
        • Contact:
          • Sonia Khan
          • Phone Number: +923224704901
        • Principal Investigator:
          • Awishbah Khan, DPT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Only female hockey players

    • Age 18-24 years
    • Athletes with at least one year experience in hockey
    • Athletes must be without previous experience in intense strength/endurance training
    • Only players who will participate in at all training sessions will be included in the statistical analysis

Exclusion Criteria:

  • Participants having injuries resulting in loss of one or more hockey matches/ training sessions in the preceding three months prior to the initiation of the study
  • Participants with the history of systemic disease
  • Participants with history of lower extremity and lumber spine pathology
  • Participants with prior surgery history

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Combined Plyometric and Endurance Training
will receive both below mentioned trainings with alternative timings
Other: Combined Plyometric and Endurance Training
this include Combined Plyometric and Endurance Training for 12 weeks
Active Comparator: Plyometric Training
First of all, the training session will be started with a warm-up period of 10min. the athlete will be asked to do gentle warm-up exercises. In the next step of training Counter movement jump for Plyometric training (CMJ will be performed with a squat starting position, that is, knees flexed to 90 ° and hands on hips. From this position, the hockey players will be required to bend their knees to a freely chosen angle and perform a maximal vertical thrust. The hands are held on the hips during the jump to avoid any effect of arm-swinging. Participants will be instructed to keep their body vertical throughout the jump, avoiding undue lateral and frontal movements, and to land with knees fully extended.) The CMJ period will be in 2 rounds each round of 8 min with 4 min break between the rounds. The training session will end with a 10min cooling period. The complete plyometric training session will be of 40mins.
Other: Plyometric Training
this include Plyometric Training for 12 weeks
Active Comparator: Endurance Training
Endurance training will be done on a cycle ergometer. Subjects will initially do six 3-min bouts of exercise with 3-min rest periods between bouts. The bouts will be done at power outputs corresponding to that which require 60 and 80% VO₂ max respectively. After 4 weeks a seventh bout will be added and after 8 weeks an eight bout. After 10 weeks 10 bouts will be done till the end of the training. Each endurance training sub-session will last for 35-45 min.
Other: Endurance training
this include Endurance Training for 12 weeks

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Speed
Time Frame: 0 week, 6 week, 12 week
will be measured by Sprint test
0 week, 6 week, 12 week
Agility
Time Frame: 0 week, 6 week, 12 week
will be measured by t test
0 week, 6 week, 12 week
Strength
Time Frame: 0 week, 6 week, 12 week
will be measured by 5 jump distance test
0 week, 6 week, 12 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Awishbah Khan, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 14, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 14, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 14, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 15, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 19, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 19, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/23/0469

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings